drugset / Trial / NCT06208683
The Immunogenicity and Safety of the Booster Doses of a Live-attenuated Mumps Vaccine in Junior High School Students
RandomizedParallel-groupOpen-labelPrevention
Summary
This study is a randomized, controlled, open-label phase Ⅳ clinical trial of a live attenuated mumps vaccine manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd. The purpose of this study is to evaluate the immunogenicity and safety of the booster doses of a mumps vaccine administrated alone and concomitantly with a quadrivalent inactivated influenza vaccine in healthy junior high school students. And the cross-neutralization of mumps vaccine immune serum and mumps virus strains
Timeline
- Start
- 2023-11-04
- Primary completion
- 2024-02-02
- Completion
- 2024-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Influenza Vaccine, inactivated, quadrivlent | Vaccine | 15 ug | — |
| Subject | Influenza Vaccine, inactivated, quadrivlent | Vaccine | 0.5 ml | — |
| Subject | MUMPS VIRUS VACCINE LIVE | Vaccine | 0.5 ml | — |